Olema Pharmaceuticals Stock (NASDAQ:OLMA)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$11.62

52W Range

$8.51 - $17.79

50D Avg

$12.01

200D Avg

$12.14

Market Cap

$679.18M

Avg Vol (3M)

$479.69K

Beta

2.03

Div Yield

-

OLMA Company Profile


Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

80

IPO Date

Nov 19, 2020

Website

OLMA Performance


OLMA Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income$-104.96M$-106.99M$-71.49M
Net Income$-96.66M$-102.59M$-70.89M
EBITDA$-104.96M$-106.99M$-71.10M
Basic EPS-$-2.56$-1.79
Diluted EPS-$-2.56$-1.79

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
GRCLGracell Biotechnologies Inc.
SANASana Biotechnology, Inc.
CGEMCullinan Oncology, Inc.
ZNTLZentalis Pharmaceuticals, Inc.
CNTACentessa Pharmaceuticals plc
LRMRLarimar Therapeutics, Inc.
MLYSMineralys Therapeutics, Inc.
ERASErasca, Inc.
OBIOOrchestra BioMed Holdings, Inc.
FENCFennec Pharmaceuticals Inc.
IRONDisc Medicine, Inc.
ANTXAN2 Therapeutics, Inc.
GLUEMonte Rosa Therapeutics, Inc.
DSGNDesign Therapeutics, Inc.
PHVSPharvaris N.V.
PEPGPepGen Inc.
MOLNMolecular Partners AG
LIFEaTyr Pharma, Inc.
NVCTNuvectis Pharma, Inc.